Ardelyx Past Earnings Performance
Past criteria checks 0/6
Ardelyx has been growing earnings at an average annual rate of 5.5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 73.1% per year.
Key information
5.5%
Earnings growth rate
25.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 73.1% |
| Return on equity | -39.6% |
| Net Margin | -53.1% |
| Next Earnings Update | 02 May 2024 |
Recent past performance updates
Recent updates
Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing
Apr 17
Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Mar 13Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 24Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance
Feb 20Ardelyx's XPHOZAH Still An Afterthought To The Pros
Jan 31Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement
Jan 10Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price
Jan 04Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt
Dec 14Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 03Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt
Jul 31Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now
Apr 17Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Mar 30Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Dec 14What To Expect For Ardelyx In The Coming Month
Oct 18Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position
Oct 04Ardelyx secures $20M financial deal with HealthCare Royalty on tenapanor potential sale
Jun 30Ardelyx Is Down, Long Live Ardelyx
Jan 28Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher
Dec 02Ardelyx: Indecisive Regulators, Frustrated Company, Gruelling Wait For Investors
Oct 25Revenue & Expenses BreakdownBeta
How Ardelyx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 124 | -66 | 134 | 0 |
| 30 Sep 23 | 134 | -27 | 103 | 0 |
| 30 Jun 23 | 83 | -56 | 89 | 0 |
| 31 Mar 23 | 63 | -66 | 81 | 0 |
| 31 Dec 22 | 52 | -67 | 77 | 0 |
| 30 Sep 22 | 9 | -114 | 75 | 0 |
| 30 Jun 22 | 5 | -135 | 73 | 0 |
| 31 Mar 22 | 4 | -153 | 75 | 0 |
| 31 Dec 21 | 10 | -158 | 69 | 0 |
| 30 Sep 21 | 11 | -151 | 66 | 0 |
| 30 Jun 21 | 12 | -125 | 56 | 0 |
| 31 Mar 21 | 13 | -105 | 43 | 0 |
| 31 Dec 20 | 8 | -94 | 33 | 0 |
| 30 Sep 20 | 8 | -85 | 29 | 0 |
| 30 Jun 20 | 8 | -91 | 28 | 0 |
| 31 Mar 20 | 6 | -91 | 26 | 0 |
| 31 Dec 19 | 5 | -95 | 24 | 0 |
| 30 Sep 19 | 3 | -103 | 23 | 22 |
| 30 Jun 19 | 0 | -104 | 22 | 40 |
| 31 Mar 19 | 0 | -100 | 23 | 56 |
| 31 Dec 18 | 3 | -91 | 24 | 0 |
| 30 Sep 18 | 45 | -53 | 24 | 64 |
| 30 Jun 18 | 44 | -50 | 24 | 62 |
| 31 Mar 18 | 44 | -53 | 23 | 66 |
| 31 Dec 17 | 42 | -64 | 23 | 75 |
| 30 Sep 17 | 0 | -106 | 23 | 150 |
| 30 Jun 17 | 0 | -114 | 21 | 134 |
| 31 Mar 17 | 0 | -117 | 21 | 114 |
| 31 Dec 16 | 0 | -112 | 19 | 94 |
| 30 Sep 16 | 0 | -98 | 18 | 0 |
| 30 Jun 16 | 0 | -87 | 17 | 0 |
| 31 Mar 16 | 18 | -50 | 15 | 0 |
| 31 Dec 15 | 24 | -30 | 14 | 39 |
| 30 Sep 15 | 30 | -16 | 12 | 0 |
| 30 Jun 15 | 38 | 2 | 11 | 0 |
| 31 Mar 15 | 29 | -6 | 9 | 0 |
| 31 Dec 14 | 32 | -3 | 7 | 0 |
| 30 Sep 14 | 34 | -4 | 6 | 1 |
| 30 Jun 14 | 33 | -5 | 5 | 3 |
| 31 Mar 14 | 31 | -7 | 5 | 6 |
| 31 Dec 13 | 29 | -7 | 4 | 0 |
Quality Earnings: ARDX is currently unprofitable.
Growing Profit Margin: ARDX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARDX is unprofitable, but has reduced losses over the past 5 years at a rate of 5.5% per year.
Accelerating Growth: Unable to compare ARDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ARDX has a negative Return on Equity (-39.6%), as it is currently unprofitable.